Early Steps in the Processing of Amyloid Precursor Protein
About the Research Project
Program
Award Type
Standard
Award Amount
$197,661
Active Dates
April 01, 2000 - April 01, 2002
Grant ID
A2000050
Summary
APP is synthesized in a part of the cell called the endoplasmic reticulum (ER), where it undergoes a number of changes. In AD, the processing of APP is altered, leading to overproduction of the amyloid protein Ab42. However, it is not yet clear what causes the production of Ab42 in the ER. Dr. Goldgaber has hypothesized that as APP is synthesized and inserted into the ER, it interacts with specialized proteins called chaperones. Chaperones are known to be important in helping newly synthesized proteins fold into their proper three-dimensional shape. In Dr. Goldgaber’s hypothesis, the interaction between APP and chaperones is required to ensure that the APP is properly modified and processed. He believes that misfolded or mutant APP may be targeted for some type of protein degradation, which could lead to the production of Ab42. He is exploring a number of approaches for studying the role of chaperones in the processing of normal and mutant APP.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD